Class action lawsuits against genetic testing companies over PGT-A
By Ruth Retassie,
PET
| 10. 21. 2024
Former IVF patients in the USA have filed class action lawsuits against several companies for misleading them about the efficacy of PGT-A.
Class action lawsuits have been filed against CooperGenomics, CooperSurgical, The Cooper Companies, Reproductive Genetic Innovations, Progenesis, and Natera by former patients to recuperate funds spent on preimplantation genetic testing for aneuploidy (PGT-A). The lawsuits allege that these companies engaged in consumer fraud and breach of warranty by selling PGT-A to IVF patients, without disclaiming that this test is unproven, experimental, and entails risks of both misdiagnosis and embryo damage during the biopsy. The plaintiffs and class action members claim they would not have purchased testing if given accurate information about its efficacy.
Paula Bliss, partner and co-founder of Justice Law Collaborative and counsel for the plaintiffs, said: 'Our clients have been forced to make consequential decisions based on PGT-A testing that was falsely marketed as having unproven benefits... we seek justice on their behalf.'
PGT-A is conducted to analyse the chromosomal makeup of embryos. The aim is to improve chances of a live birth...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...
